Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Abingdon Health (LSE:ABDX) Secures USD 2m Multiplex Diagnostic Test Contract

Abingdon Health plc (LSE:ABDX) has secured a new contract with an expected value of approximately USD 2m. The agreement, structured as a Master Service Agreement (MSA) with a US-based company, covers the development, scale-up, and technical transfer of a semi-quantitative, multiplex lateral flow test …

Team Kalkine | 10 November 2025

Hikma Pharmaceuticals (LSE:HIK) Receives Consistent ‘Buy’ Ratings from Leading Brokerages

Hikma Pharmaceuticals PLC (LSE:HIK), the multinational pharmaceutical group, continues to attract favorable analyst sentiment, with key brokerages maintaining ‘Buy’ recommendations, might be following the company’s interim financial performance for the six months ended 30 June 2025.

Team Kalkine | 10 November 2025

Renalytix Plc (LSE:RENX) Reports Revenue Growth and Partnership Progress in FY25

Renalytix plc (LSE:RENX), a precision medicine diagnostics company, announced its audited results for the fiscal year ended 30 June 2025. The company reported totalrevenueof USD 3.0 million, up 30% from FY2024 (USD 2.3 million), supported by testing growth and increased pharmaceutical services revenue.

Team Kalkine | 03 November 2025

Optima Health (LSE:OPT) Reports Revenue Increase and Platform Enhancement Plan in H1

Optima Health plc (LSE:OPT), a UK-based provider of technology-enabled corporate health and wellbeing services, announced its unaudited trading update for the half year ended 30 September 2025 (“H1 26”).

Team Kalkine | 03 November 2025

Broker Issues ‘Buy’ Rating on Reckitt Benckiser (LSE:RKT) with Target Price of GBP 6,700

Rothschild & Co Redburn (LSE:RKT) has issued a‘Buy’rating on Reckitt Benckiser Group plc (LSE:RKT), setting a target price of GBP 6,700, reflecting an upside potential of 13.75% from current levels. The rating follows the company’s announcement of its Q3 2025 performance, highlighting sustained growth …

Sonal Goyal | 28 October 2025

MedPal AI (AIM:MPAL) Opens 24/7 AI-Powered National Distribution Centre

MedPal AI Plc (AIM:MPAL) has officially opened a new 24/7 AI-powered distribution centre at Ecotech Business Park, Swaffham. The development follows the acquisition of key assets from Universal Pharmacy Limited, including a Distance Selling Pharmacy (DSP) licence and a warehouse unit. With the GPhC …

Team Kalkine | 22 October 2025

GSK (LSE:GSK) Reports Positive Phase III Data for Low Carbon Ventolin Inhaler

GSK plc (LSE:GSK) announced positive Phase III data from its clinical programme for a next-generation version of its metered dose inhaler (MDI), Ventolin (salbutamol). The study demonstrated that the salbutamol MDI containing the innovative low-carbon propellant HFA-152a has therapeutic equivalence and a comparable safety …

Team Kalkine | 22 October 2025

AstraZeneca (LSE:AZN) Reaches New US Government Deal to Cut Drug Costs us

AstraZeneca (LSE:AZN) is a global, research-driven biopharmaceutical company dedicated to the discovery, development, and marketing of innovative prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals. Headquartered in Cambridge, UK, the company’s therapies improve the lives of patients in more than 125 countries.

Team Kalkine | 13 October 2025

Aptamer Group (LSE:APTA) Signs GBP 360,000 Worth Radiopharmaceutical Contract, Stock up 23%

Aptamer Group plc(LSE:APTA) Group produces Optimer® binders, molecules that function similarly to antibodies by binding to specific targets in the body. These binders are applied in therapeutics, diagnostics, and research tools, offering advantages such as high stability, consistent performance, and lower costs compared with …

Team Kalkine | 08 October 2025

Renalytix (LSE:RENX) to Raise Minimum £4 Million via Placing, Subscription and Retail Offer

Renalytix plc (LSE:RENX) (OTCQB:RNLXY), a precision medicine company focused on early-stage risk assessment in chronic kidney disease (CKD), has announced its intention to raise a minimum of £4.0 million in gross proceeds. The capital will be secured through a placing, a subscription of new …

Team Kalkine | 22 September 2025

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions